Skip to content

PROPANC BIOPHARMA, INC.: 10-K filed 2012-10-15

What PROPANC BIOPHARMA, INC. reported in its annual report filed 2012-10-15 (fiscal FY 2012): 33 published measures, 83 facts as tagged in accession 0001354488-12-005291.

This filing

Form
10-K (annual report)
Filed
2012-10-15
Fiscal period
fiscal FY 2012
Accession
0001354488-12-005291 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-3046,268USD
At 2011-06-3010,814,158USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-06-30584,187USD
At 2011-06-30306,849USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-30-537,919USD
At 2011-06-3010,507,309USD
At 2010-06-30-186,903USD
At 2009-06-30-409,391USD
At 2008-06-3085,134USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-11,434,375USD366
2007-10-15 to 2012-06-30-15,280,715USD1721
2010-07-01 to 2011-06-30-2,151,977USD365
2009-07-01 to 2010-06-30-842,487USD365
2008-07-01 to 2009-06-30-443,849USD365
2007-10-15 to 2008-06-30-408,027USD260

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-170,278USD366
2007-10-15 to 2012-06-30-2,522,789USD1721
2010-07-01 to 2011-06-30-1,395,376USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2007-10-15 to 2012-06-3014,786USD1721
2010-07-01 to 2011-06-303,506USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-07-01 to 2012-06-30170,331USD366
2007-10-15 to 2012-06-302,608,382USD1721
2010-07-01 to 2011-06-301,424,118USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2007-10-15 to 2012-06-30-40,512USD1721
2010-07-01 to 2011-06-30-29,232USD365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-173,928USD366
2007-10-15 to 2012-06-30-258,509USD1721
2010-07-01 to 2011-06-30-84,581USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-06-304,617USD
At 2011-06-306,655USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2007-10-15 to 2012-06-30299,737USD1721

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-11,589,770USD366
2007-10-15 to 2012-06-30-15,354,980USD1721
2010-07-01 to 2011-06-30-2,235,366USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-3041,651USD
At 2011-06-3010,779,940USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-07-01 to 2012-06-302,967USD366
2007-10-15 to 2012-06-30174,163USD1721

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-30584,187USD
At 2011-06-30306,849USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-06-30192,473USD
At 2011-06-3027,717USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2012-06-3011,589,770USD366
2007-10-15 to 2012-06-3015,385,954USD1721
2010-07-01 to 2011-06-302,235,366USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2012-06-305,279USD366
2007-10-15 to 2012-06-30643,323USD1721
2010-07-01 to 2011-06-30385,777USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-06-3072,705,569shares
At 2011-06-3071,915,890shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-06-3015,029,326USD
At 2011-06-3014,401,919USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-06-30-358,917USD
At 2011-06-30-120,185USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-06-3016,143USD
At 2011-06-3016,837USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-06-30-11,526USD
At 2011-06-30-10,182USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-06-3038,520USD
At 2011-06-3010,777,951USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2012-06-3016,744USD
At 2011-06-3010,832USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-11,673,107USD366
2007-10-15 to 2012-06-30-15,639,632USD1721
2010-07-01 to 2011-06-30-2,171,575USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2012-06-3011,571,613USD366
2007-10-15 to 2012-06-3014,686,051USD1721
2010-07-01 to 2011-06-301,837,668USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-07-01 to 2012-06-301,792USD366
2007-10-15 to 2012-06-3010,149USD1721
2010-07-01 to 2011-06-301,857USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-18,533USD366
2007-10-15 to 2012-06-30-184,244USD1721
2010-07-01 to 2011-06-30-1,192USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2011-07-01 to 2012-06-30-173,928USD366
2010-07-01 to 2011-06-30-84,581USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-07-01 to 2012-06-3028,025USD366
2007-10-15 to 2012-06-301,479,675USD1721
2010-07-01 to 2011-06-301,359,840USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2007-10-15 to 2012-06-30-664USD1721

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-07-01 to 2012-06-30161,623USD366
2007-10-15 to 2012-06-30181,423USD1721
2010-07-01 to 2011-06-30-23,289USD365

Inspect the source

Entity
PROPANC BIOPHARMA, INC. / CIK 0001517681
Captured
2026-09-20T09:14:07.933Z
SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))